Examiner: PARKIN, JEFFREY S

Tech Center 1600 • Art Units: 1646 1648 1671

This examiner grants 64% of resolved cases

Analysis

Examiner PARKIN, JEFFREY S is assigned to Art Unit 1646 within Tech Center 1600. The data shows that the examiner has 870 resolved cases, with an allowance rate of 63.6 percent. This 63.6 percent allowance rate serves as a baseline for applicants during the examination process. The 870 resolved cases provide a record of the examiner's work in Art Unit 1646. These figures establish the prosecution environment for this unit.

The median days to allowance for successful applications is 1269. An interview lift of 21.7 percent is recorded, which indicates the change in the probability of allowance following an interview. Practitioners can use this 21.7 percent lift to evaluate the impact of communication. The 1269 median days to allowance helps in planning the prosecution timeline. The metrics are derived from the examiner's professional history in Tech Center 1600.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

63.7%

Allow Rate

+3.7% vs TC avg

907

Total Applications

+21.7%

Interview Lift

1270

Avg Prosecution Days

Based on 874 resolved cases, 2023–2026

Rejection Statute Breakdown

4.1%

§101 Eligibility

7.6%

§102 Novelty

25.8%

§103 Obviousness

52.2%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
18252590	NEW FELINE HERPES VIRUS VACCINE	Non-Final OA	Boehringer Ingelheim Vetmedica GmbH
18014645	SAMPLING KITS AND METHODS FOR DETECTING RESPIRATORY PATHOGENS	Non-Final OA	SEEGENE, INC.
18017165	METHODS FOR ASSESSING THE SEVERITY AND PROGRESSION OF SARS-COV2 INFECTIONS USING CELL-FREE DNA	Non-Final OA	CORNELL UNIVERSITY
17640327	COMBINATION ANTIVIRAL THERAPY FOR MEASLES	Non-Final OA	Cornell University
17358523	METHODS OF DETECTING SARS-COV-2, INFLUENZA, AND RSV	Final Rejection	Cepheid
18300973	Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use	Non-Final OA	Inovio Pharmaceuticals, Inc.
16652867	VECTORS WITH PROMOTER AND ENHANCER COMBINATIONS FOR TREATING PHENYLKETONURIA	Non-Final OA	American Gene Technologies International Inc.
17955599	RNA DETERMINANTS FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS	Non-Final OA	MeMed Diagnostics Ltd.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy